Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Clinical Development Biologics Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Trending T Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Clinical Development Biologics Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Stories Sponsored HLAh iPSC Lines Help Address Cell Therapy Immunogenicity iPSC lines are well suited for use as starting material for allogeneic cell therapies through immunogenicity reducing strategies. Sponsored Quality Considerations for a Growing Gene Therapy Field Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews. Sponsored Balancing Quality Grade Plasmids and Expedited Timelines for Advanced Therapies The key to success in developing and bringing mRNA-, DNA-, viral vector- and cell-based therapies to the market is having a partner like Catalent Sponsored Why Integrated Partners are Critical to Cell and Gene Therapy Success Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, and more. Sponsored Avoiding Gene Therapy CMC and Clinical Supply Issues Gene therapy manufacturing and clinical supply strategies should be in place early to avoid potential late-stage development delays. Sponsored The Benefit of an Experienced Manufacturing Partner: Leveraging Scale-up and Technology Expertise for Allogeneic Cell Therapy Manufacturing Increased demands, cell manufacturing complexity, and tight timelines: Time for the right allogeneic manufacturing partner. Sponsored Partnering Early for Cell and Gene Therapy Manufacturing The importance of establishing a manufacturing strategy and leveraging the expertise of a CDMO early in the cell and gene therapy development timeline
Sponsored HLAh iPSC Lines Help Address Cell Therapy Immunogenicity iPSC lines are well suited for use as starting material for allogeneic cell therapies through immunogenicity reducing strategies.
Sponsored Quality Considerations for a Growing Gene Therapy Field Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews.
Sponsored Balancing Quality Grade Plasmids and Expedited Timelines for Advanced Therapies The key to success in developing and bringing mRNA-, DNA-, viral vector- and cell-based therapies to the market is having a partner like Catalent
Sponsored Why Integrated Partners are Critical to Cell and Gene Therapy Success Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, and more.
Sponsored Avoiding Gene Therapy CMC and Clinical Supply Issues Gene therapy manufacturing and clinical supply strategies should be in place early to avoid potential late-stage development delays.
Sponsored The Benefit of an Experienced Manufacturing Partner: Leveraging Scale-up and Technology Expertise for Allogeneic Cell Therapy Manufacturing Increased demands, cell manufacturing complexity, and tight timelines: Time for the right allogeneic manufacturing partner.
Sponsored Partnering Early for Cell and Gene Therapy Manufacturing The importance of establishing a manufacturing strategy and leveraging the expertise of a CDMO early in the cell and gene therapy development timeline
